


**BEST-IN-CLASS
SARS-COV-2
ANTIBODY TESTING
BY QUOTIENT**



BEST-IN-CLASS PERFORMANCE

The MosaiQ COVID-19 Antibody Microarray tests for IgM and IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, offering one of the earliest antibody detection tests available.


Independent and internal studies confirmed the best-in-class performance, with 100% sensitivity and 99.8% specificity, in samples of 507 and 431 respectively.

The MosaiQ COVID-19 Antibody Microarray has an IVD CE mark as of 1 May 2020. US FDA EUA is pending as of May 2020.

100%
sensitivity


99.8%
specificity

ILLUSTRATIVE CASE OF A POTENTIAL RESPONSE TO SARS-COV-2




DETECTS NEUTRALIZING ANTIBODIES

The MosaiQ COVID-19 Antibody Microarray uses spike protein antigens that bind to ACE2 receptors on human cells, starting infection. An alternative would be to target the nucleocapsid protein, which is responsible for the replication of the virus once infection has occurred. However, antibodies to the spike glycoprotein have a more comprehensive role, as they interfere with the ability of the virus to bind, infect and replicate in human cells. An assay identifying antibodies to the nucleocapsid protein may not detect the more important antibodies neutralizing the spike protein, which is why the spike protein antibodies are targeted by Quotient's MosaiQ COVID-19 Antibody Microarray¹.



STREAMLINED AND EFFICIENT



The MosaiQ COVID-19 Antibody Microarray combines with the multiplexing, high-throughput MosaiQ™ instrument to quickly and accurately evaluate samples in central laboratories.

- ◆ Each microarray can generate reactions on up to **132 printed biological markers**
- ◆ Up to **3,000 microarrays** can be tested in 24 hours
- ◆ Results are provided **every 24 seconds** after the first result
- ◆ **Only 5µl of serum or plasma tested per sample**
- ◆ **Walk-away solution** using continuous sample loading
- ◆ MosaiQ microarrays are **stored at room temperature**, saving expensive cold storage space

FUTURE PROOF

The MosaiQ system can utilize up to four types of different microarrays simultaneously to allow for true multiplex testing. Quotient is continually working on expanding the system's capabilities by enhancing the microarrays available and seeking further approvals in areas such as immunohematology, infectious disease, molecular diagnostics and beyond.

BROAD CLINICAL UTILITY



CONFIRMATION OF SEROCONVERSION

As early as 2-7 days post PCR MosaiQ, in conjunction with molecular or PCR testing can confirm SARS-CoV-2 virus infection. Additionally, if PCR testing is negative, but patient is symptomatic, antibody testing can provide evidence of immune response.



CONFIRMATION OF IMMUNE RESPONSE

20+ days post symptoms MosaiQ can confirm immune response in recovering or convalescent patients.



RESEARCH

The spike protein antigen choice progresses the development of therapeutic options, such as the identification of serum likely to be rich in neutralizing antibodies, and vaccine trials including assessment of post-vaccination responders and selection of trial subjects.



PUBLIC HEALTH AND POLICY DEVELOPMENT

MosaiQ fosters epidemiological research, enabling the survey of population response to SARS-CoV-2 within localized and generalized cohorts.



SPECIFICATIONS

TECHNICAL DATA

Installation dimensions and weight of the MosaiQ instrument:

Width	Closed: 174 cm (68.51 in)
Opened (only for servicing)	354 cm (139.38 in)
Depth	Closed: 90 cm (35.44 in)
Opened	165 cm (64.97 in)
Height	166 cm (65.36 in)
Weight	285 kg (628.3 lb)



To learn more, visit us at:
www.quotientbd.com
or email us with suggestions or ideas: covid19@quotientbd.com

Menus and capabilities are subject to change.
Not all methods may be available in all territories.

Subject to regulatory clearance.



1. The Lancet. (April 4 2020). Volume 395. *Developing antibody tests for SARS-CoV-2.* Anna Petherick



Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and available for distribution in Europe including Switzerland, and the UK. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

June 2020. GFD #0.0021.v1